Last reviewed · How we verify
Long-acting Risperidone microspheres injection — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Long-acting Risperidone microspheres injection (Long-acting Risperidone microspheres injection) — Hospital Authority, Hong Kong.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Long-acting Risperidone microspheres injection TARGET | Long-acting Risperidone microspheres injection | Hospital Authority, Hong Kong | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Long-acting Risperidone microspheres injection CI watch — RSS
- Long-acting Risperidone microspheres injection CI watch — Atom
- Long-acting Risperidone microspheres injection CI watch — JSON
- Long-acting Risperidone microspheres injection alone — RSS
Cite this brief
Drug Landscape (2026). Long-acting Risperidone microspheres injection — Competitive Intelligence Brief. https://druglandscape.com/ci/long-acting-risperidone-microspheres-injection. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab